Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01105117 · ClinicalTrials.gov registry record · Phase 4
Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
A Phase 4 study of Pulmonary Arterial Hypertension, sponsored by Actelion.
- Completed
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
- 7
- Study locations
NCT01105117: Completed Phase 4 study of Pulmonary Arterial Hypertension, sponsored by Actelion.
NCT01105117 is a Phase 4 study of Pulmonary Arterial Hypertension that has completed, run by Actelion. The registered enrollment target is 2 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (100% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01105117, a Phase 4 study of Pulmonary Arterial Hypertension, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is an open-label, non-randomized extension to study AC-066A401. The study will assess safety and tolerability of ACT-385781A and Flolan (epoprostenol sodium) while providing a means for continuing treatment after ending participation in study AC-0066A401.
Conditions Studied
Interventions
- DRUG ACT-385781A (Actelion Epoprostenol)
- DRUG Flolan®
Study Locations (7)
Texas
- University of Texas Southwestern Medical Center - Dallas
- Baylor College of Medicine - Houston
California
- University of California - San Diego - La Jolla
Colorado
- University of Colorado - Denver - Aurora
North Carolina
- Duke University Medical Center - Durham
Pennsylvania
- University of Pennsylvania-Penn Presybyterian Medical Center - Philadelphia
Tennessee
- Vanderbilt Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
What the finished NCT01105117 record still lists
NCT01105117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 2 interventions - of which ACT-385781A (Actelion Epoprostenol) is the first listed.
NCT01105117 lists 7 locations in 6 states (Texas, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT01105117 about?
NCT01105117 is a clinical study titled "Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401". This is an open-label, non-randomized extension to study AC-066A401. The study will assess safety and tolerability of ACT-385781A and Flolan (epoprostenol sodium) while providing a means for continuing treatment after ending participation in study AC-0066A401.
What is the current status of trial NCT01105117?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2010-05. Estimated completion is 2011-12.
What conditions does trial NCT01105117 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT01105117?
The interventions under investigation include: ACT-385781A (Actelion Epoprostenol) (DRUG), Flolan® (DRUG).
Who is sponsoring clinical trial NCT01105117?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01105117 being conducted?
This trial has 7 study locations across California, Colorado, North Carolina, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01105117's enrollment target sits among peer trials
2 64th of 63 the lowest of 63 other Pulmonary Arterial Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Arterial Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 4
-
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 4
-
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
COMPLETED · Phase 4
-
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
COMPLETED · Phase 4
-
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
COMPLETED · Phase 4
-
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia